Segall Bryant & Hamill’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
Segall Bryant & Hamill's TVTX Position: Q3 2026 in Review
Segall Bryant & Hamill reduced its Travere Therapeutics (TVTX) stake by 4.9% in Q3 2026, selling an estimated $80.2K and leaving 25,747 shares worth $1.52M. The position accounts for 0.02% of the portfolio, ranked #508.
Segall Bryant & Hamill first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.54M in Q2 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- Segall Bryant & Hamill held 25,747 shares of Travere Therapeutics worth $1.52M as of Q3 2026.
- Segall Bryant & Hamill sold 1,313 Travere Therapeutics shares in Q3 2026, an estimated $80.2K.
- Travere Therapeutics made up 0.02% of Segall Bryant & Hamill's portfolio in Q3 2026, its #508 holding.
- Segall Bryant & Hamill first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Segall Bryant & Hamill's Travere Therapeutics position peaked at $1.54M in Q2 2026.
- 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on Segall Bryant & Hamill's 13F filing for Q3 2026, filed 16 Nov 2026.